Recently, some studies have proposed that the molecular mechanisms of resistance to GCs in ALL may be associated with RAS-pathway activating mutations29,30 and NALP3 inflammasome upregulation and CASP1 cleavage of the GC receptor31. This evidence concerns the gene CASP1 and acute lymphoblastic leukemia.